[go: up one dir, main page]

DE69632949D1 - Die aktivierung von rezeptoren durch gas6 - Google Patents

Die aktivierung von rezeptoren durch gas6

Info

Publication number
DE69632949D1
DE69632949D1 DE69632949T DE69632949T DE69632949D1 DE 69632949 D1 DE69632949 D1 DE 69632949D1 DE 69632949 T DE69632949 T DE 69632949T DE 69632949 T DE69632949 T DE 69632949T DE 69632949 D1 DE69632949 D1 DE 69632949D1
Authority
DE
Germany
Prior art keywords
gas6
receptors
activation
polypeptides
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632949T
Other languages
English (en)
Other versions
DE69632949T2 (de
Inventor
Jian Chen
R Glenn Hammonds
Paul J Godowski
Melanie R Mark
Jennie P Mather
Ronghao Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/402,253 external-priority patent/US6211142B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69632949D1 publication Critical patent/DE69632949D1/de
Publication of DE69632949T2 publication Critical patent/DE69632949T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69632949T 1995-03-10 1996-03-05 Die aktivierung von rezeptoren durch gas6 Expired - Lifetime DE69632949T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US402253 1995-03-10
US08/402,253 US6211142B1 (en) 1995-03-10 1995-03-10 Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US43886195A 1995-05-10 1995-05-10
US438861 1995-05-10
PCT/US1996/003031 WO1996028548A1 (en) 1995-03-10 1996-03-05 Receptor activation by gas6

Publications (2)

Publication Number Publication Date
DE69632949D1 true DE69632949D1 (de) 2004-08-26
DE69632949T2 DE69632949T2 (de) 2005-07-28

Family

ID=27017784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632949T Expired - Lifetime DE69632949T2 (de) 1995-03-10 1996-03-05 Die aktivierung von rezeptoren durch gas6

Country Status (11)

Country Link
US (1) US6169070B1 (de)
EP (1) EP0815224B1 (de)
JP (1) JP3342873B2 (de)
AT (1) ATE271606T1 (de)
AU (1) AU712585B2 (de)
CA (1) CA2214629C (de)
DE (1) DE69632949T2 (de)
ES (1) ES2225874T3 (de)
IL (1) IL117425A0 (de)
MX (1) MX9706827A (de)
WO (1) WO1996028548A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
AU3375199A (en) * 1998-04-01 1999-10-18 Genentech Inc. Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
CZ20003767A3 (cs) * 1998-04-15 2002-01-16 Lexigen Pharmaceuticals Corp. Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CZ20014123A3 (cs) * 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
CA2399832C (en) * 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
EP1199081A1 (de) * 2000-10-20 2002-04-24 Vlaams Interuniversitair Instituut voor Biotechnologie Inhibierung von gas6 (growth arrest-specific gene) oder gas6 Rezeptor Fonction für die Prevention und Behandlung von thromboembolischen Erkrankungen
CA2412845C (en) * 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL206701B1 (pl) * 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002090566A2 (en) * 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
GB2378899A (en) * 2001-08-25 2003-02-26 Thromb X N V Treatment of anemia
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
EP1500400A4 (de) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Arzneimittel mit antikörper-zusammensetzung
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein
WO2004108748A2 (en) * 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US20060183671A1 (en) * 2003-07-17 2006-08-17 Anne Angelillo-Scherrer Treatment of anemia
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1819728B1 (de) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7-varianten mit reduzierter immunogenität
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
US20100266604A1 (en) * 2007-11-09 2010-10-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
BRPI1016204A2 (pt) * 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2023212664A1 (en) * 2022-04-27 2023-11-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Synapse surgery tools and associated methods for neural circuit-specific synapse ablation and modification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells

Also Published As

Publication number Publication date
ES2225874T3 (es) 2005-03-16
EP0815224A1 (de) 1998-01-07
CA2214629A1 (en) 1996-09-19
DE69632949T2 (de) 2005-07-28
WO1996028548A1 (en) 1996-09-19
AU712585B2 (en) 1999-11-11
CA2214629C (en) 2001-07-10
JPH10505507A (ja) 1998-06-02
EP0815224B1 (de) 2004-07-21
AU5183696A (en) 1996-10-02
JP3342873B2 (ja) 2002-11-11
ATE271606T1 (de) 2004-08-15
US6169070B1 (en) 2001-01-02
IL117425A0 (en) 1996-07-23
MX9706827A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
ATE271606T1 (de) Die aktivierung von rezeptoren durch gas6
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
WO1999000410A3 (en) Human extracellular matrix proteins
EP2016953A3 (de) Vaskuläre endotheliale Zellwachstumsfaktor-Antagonisten und Verwendungen
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
PT1612265E (pt) Construções de tecidos por bioengenharia e métodos de produção e utilização das mesmas
AR013201A1 (es) Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u
CA2413156A1 (en) Expression vectors
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
GB2386120A (en) Differentiated cells suitable for human therapy
AU4921897A (en) Identification and expression of insect steroid receptor DNA sequences
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
GB2331753A (en) Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
MX9802730A (es) Agonistas receptores hematopoyeticos multifuncionales.
GB2322132B (en) Keratinocyte growth factor-2 products
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
DE69934399D1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen
MX9700255A (es) Metodo para identificar acidos nucleicos que codifican las proteinas activadoras del promotor c-fos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition